» Authors » Koji Uchino

Koji Uchino

Explore the profile of Koji Uchino including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 1330
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sato M, Tateishi R, Zohar Y, Sato J, Watadani T, Moriyama M, et al.
PLoS One . 2025 Jan; 20(1):e0317469. PMID: 39823502
Objective: This study aimed to introduce and evaluate a novel software-based system, BioTrace, designed for real-time monitoring of thermal ablation tissue damage during image-guided radiofrequency ablation for hepatocellular carcinoma (HCC)....
2.
Sato M, Tateishi R, Moriyama M, Fukumoto T, Yamada T, Nakagomi R, et al.
Gastro Hep Adv . 2024 Aug; 1(1):29-37. PMID: 39129938
Background And Aims: Radiofrequency ablation (RFA) is a widely accepted, minimally invasive treatment for hepatocellular carcinoma (HCC). This study aimed to develop a machine learning (ML) model to predict the...
3.
Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, et al.
Sci Rep . 2024 Feb; 14(1):2826. PMID: 38310156
The number of cancer cases diagnosed during the coronavirus disease 2019 (COVID-19) pandemic has decreased. This study investigated the impact of the pandemic on the clinical practice of hepatocellular carcinoma...
4.
Minami T, Sato M, Toyoda H, Yasuda S, Yamada T, Nakatsuka T, et al.
J Hepatol . 2023 Sep; PMID: 37716372
Background And Aims: Accurate risk stratification for hepatocellular carcinoma (HCC) after achieving a sustained viral response (SVR) is necessary for optimal surveillance. We aimed to develop and validate a machine...
5.
Sato M, Moriyama M, Fukumoto T, Yamada T, Wake T, Nakagomi R, et al.
Hepatol Int . 2023 Sep; 18(1):131-137. PMID: 37689614
Introduction: Radiofrequency ablation (RFA) is a widely accepted, minimally invasive treatment modality for patients with hepatocellular carcinoma (HCC). Accurate prognosis prediction is important to identify patients at high risk for...
6.
Yoshida H, Ohki T, Kanezaki M, Teratani T, Sato S, Obi S, et al.
BMC Gastroenterol . 2023 Jul; 23(1):250. PMID: 37488476
Background: Platelet (PLT) transfusion was the most practical way to increase patients' PLT counts before invasive hepatic procedures such as radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). A novel drug...
7.
Nakatsuka T, Nakagawa H, Uchino K, Rokutan H, Tanaka M, Moriyama M, et al.
Hepatol Res . 2023 Jul; 53(11):1117-1125. PMID: 37486025
Aim: Radiofrequency ablation (RFA) is regarded as a first-line treatment for hepatocellular carcinoma (HCC) at an early stage. When treated with RFA, tumor biopsy may not be performed due to...
8.
Wake T, Tateishi R, Moriyama M, Fukumoto T, Yamada T, Nakagomi R, et al.
Hepatol Res . 2023 Feb; 53(7):675-680. PMID: 36810930
Aim: The aim of this study was to evaluate the effects of steroids on ischemic complications after radiofrequency ablation. Methods: A total of 58 patients with ischemic complications were divided...
9.
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, et al.
J Gastroenterol . 2022 Jul; 57(8):587-597. PMID: 35788887
Background: We developed a nationwide database that stores data of patients with primary liver cancer (PLC) and decompensated cirrhosis (DC) on an admission basis. Methods: A database was constructed using...
10.
Nakagomi R, Tateishi R, Mikami S, Wake T, Kinoshita M, Nakatsuka T, et al.
PLoS One . 2021 Nov; 16(11):e0259641. PMID: 34797828
Background And Aim: Prophylactic administration of antibiotics within 24 hours of surgery is recommended to reduce the risk of infection. We conducted a prospective study to compare the efficacy of...